|
|
Media partners 
We work with leading magazines and publishers in this arena. If you are interested in becoming a media partner for this event please contact:
Julie Phillips, Marketing Manager
Email: julie.phillips@terrapinn.com
Tel: 02075394336
Fax: 02072421508
|
The International Vaccine Institute is founded on the belief that health in developing countries can be dramatically improved by the development, introduction and use of new and improved vaccines and that these vaccines should be developed through a dynamic interaction among science, public health, and business. The International Vaccine Institute will be a center of science for the public interest where this dynamic interaction can take place through research, training, technical assistance, service provision, and information dissemination.
Over 100 years of vaccine experience in the public domain
The Netherlands Vaccine Institute (NVI) was established in January 2003 as the result of the merger between the government-run vaccine production unit, SVM, and the Vaccine Division of the National Institute for Public Health and the Environment (RIVM). This new institute reflected more than 100 years of extensive knowledge and experience gained through research and production.
The NVI is one of the few government-based vaccine institutes left in the world. The Dutch government opted for an NVI that would be sufficiently independent of commercial vaccine suppliers in the case of vaccine shortages.
Thomson Pharma was developed to help pharmaceutical companies make better decisions faster.
It integrates information from Thomson Scientific with information from other Thomson sources, including the Financial, Healthcare and Legal and Regulatory groups. Thomson Pharma's core content areas include drug information, intellectual property data, literature and news, company data, chemical information, sequence data and drug target information, enhanced with value added content resources and powerful search tools. www.thomsonpharma.com
The vaccine field has been transformed by the technological advances of the past decade. We are now beginning to visualize the future impact of vaccines, in terms of both healthcare and economics. Expert Review of Vaccines is dedicated to providing structured, informed commentary on the development and application of new vaccines and vaccine technologies. It publishes the key information needed by decision makers in the development and application of vaccines – from concept to the clinic.
For more information please contact info@future-drugs.com or visit our website www.future-drugs.com
Every weekly issue of Cancer Drug News reports the important news on the companies, products, alliances and research that are shaping global cancer markets with regular sections on cancers affecting the brain, breast, GI tract, genito-urinary system, gynaecological system, blood and lung as well as melanoma/sarcoma.
For full details/sample issue: www.espicom.com/cdn
Drug Delivery Insight: a complete review of the latest commercial and product developments.
Drug Delivery Insight (DDI) takes the hard work out of staying in touch with the companies, products, alliances and research activities shaping the industry. For more information on DDI and to download your free copy visit http://www.espicom.com/ddi
Pharmalicensing is the world’s number one biopharmaceutical partnering resource. Actively supporting in and out licensing activity, Pharmalicensing.com is used by over 30, 000 companies each month. Through its Partneringdesk database products, Pharmalicensing provides key business intelligence for biopharma dealmakers. Pharmalicensing is part of Bridgehead International
Current HIV Research aims to cover all the latest and outstanding developments of HIV research. We invite comprehensive review articles and novel and pioneering work in the basic and clinical fields on all areas of HIV research, including virus replication and gene expression, HIV assembly, virus-cell interaction, viral pathogenesis, epidemiology and transmission, anti-retroviral therapy and adherence, drug discovery, the latest developments in HIV/AIDS vaccines and animal models, mechanisms and interactions with AIDS related diseases, and prevention of viral infection. Each issue of the journal contains a series of timely in-depth reviews and original research written by leaders in the field covering a range of current topics on HIV research. Periodically, the journal will invite guest editors to devote an issue on a particular area of HIV research of great interest that increases our understanding of the virus and its complex interaction with the host.
BioCentury Publications Inc. provides business-oriented information services for life science executives and investors. The company publishes BioCentury,
the Bernstein Report on BioBusiness, which specializes in analysis and commentary on issues affecting biotechnology industry development, corporate
performance and shareholder value. BioCentury also publishes BioCentury Extra, a web-based daily news service, the weekly BioCentury Part II, the industry’s most complete and well-organized compendium of corporate, clinical and financial transactions, and provides web-based business-oriented databases, and organizes bioindustry conferences on Wall Street, in Europe and Asia. To learn more about BioCentury, please visit our website at www.biocentury.com.
|
|
|
|
